Whitehawk Therapeutics, Inc. (WHWK)
NasdaqCM · USD · Healthcare · Biotechnology
$3.24 (+3.18%) as of
Key statistics
- Market cap
- 184.71M
- Forward P/E
- -3.28
- EPS (TTM)
- -1.1200
- Dividend yield
- 0.00%
- 52-week range
- 1.9700 – 5.4950
- Beta
- 0.91
- Profit margin
- 0.00%
- Analyst target
- $7.71
- Volume
- 141.18k
About Whitehawk Therapeutics, Inc.
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Morristown, NJ, United States
- Employees
- 32
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.